pramipexole + Bromocriptine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinson's Disease
Conditions
Parkinson's Disease
Trial Timeline
Feb 1, 2012 → May 23, 2016
NCT ID
NCT01673724About pramipexole + Bromocriptine
pramipexole + Bromocriptine is a approved stage product being developed by Sandoz Group for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01673724. Target conditions include Parkinson's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01673724 | Approved | Completed |
Competing Products
20 competing products in Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 52 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 77 |